fa عمومى General پژوهشي Research <div class="rounded" style="background: rgb(238, 238, 238); border: 1px solid rgb(204, 204, 204); padding: 5px 10px; text-align: justify;"><span style="line-height:2;"><span style="font-family:Times New Roman;"><span style="font-size:14px;"><span style="letter-spacing:-0.2pt"><span style="color:#2980b9;"><b>Background and Objective: </b></span>Multiple sclerosis<b> </b>(MS) is an autoimmune-mediated demyelinating disease. MS is a heterogeneous and complex disease with various degrees of progression and treatment responses to routine drugs. Recently, statins have been used for the treatment of MS due to their high efficacy and low side effects. This study aimed to investigate <i>CYBB</i> expression in MS patients undergoing rosuvastatin therapy. </span><br> <span style="letter-spacing:-0.2pt"><b><span style="color:#2980b9;">Methods:</span> </b>This study was conducted on MS patients (n=24). Participants received 20 mg/day of rosuvastatin for 90 days. The Expanded Disability Status Scale (EDSS) and <i>CYBB</i> gene expression were measured before and after treatment with rosuvastatin. For gene expression measurement, total <strong style="font-weight:normal">ribonucleic acid</strong> was isolated from MS patients&#39; blood. After complementary DNA (cDNA) synthesis, qualitative expression level of the <i>CYBB</i> gene was measured by real-time polymerase chain reaction technique (Roche LightCycler&reg; 96). Additional information of patients was obtained and recorded in a checklist. Data were analyzed with statistical software of GraphPad (version 6) and SPSS (version 23) and the significant level was <i>P</i><0.05. </span><br> <span style="letter-spacing:-0.2pt"><span style="color:#2980b9;"><b>Results: </b></span>Participants were 24 MS patients, including 5 (28.2%) males and 19 (79.2%) females with an average age of 44.25&plusmn;11.12 years. No significant improvement was observed in the EDSS of patients following rosuvastatin therapy (<i>P</i>>0.05). Also, no significant correlation was observed between <i>CYBB</i> expression level and EDSS (<i>P</i>>0.05). <i>CYBB</i> was significantly upregulated in MS patients after rosuvastatin therapy (<i>P</i> < 0.001), while no significant change was observed in the housekeeping gene expression (<i>P</i>>0.05).</span><br> <b><span style="color:#2980b9;">Conclusion:</span> </b>The changes in <i>CYBB</i> gene expression occur earlier than any detectable clinical changes, such as those measured by EDSS.</span></span></span></div> CYBB, Multiple sclerosis (MS), NADPH oxidase complex (NOX2), Rosuvastatin 0 0 http://ajpr1.umsha.ac.ir/browse.php?a_code=A-10-2-9&slc_lang=fa&sid=1 Rayeheh Shams 100319475328460058 100319475328460058 Yes Pharmaceutical Sciences Research Center, Institute of Cancer, Avicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, Iran Maryam Etminaniesfahani 100319475328460059 100319475328460059 No Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran Mehrdokht Mazdeh 100319475328460060 100319475328460060 No Neurophysiology Research Center, Institute of Neuroscience and Mental Health, Avicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, Iran Alireza Soltanian 100319475328460061 100319475328460061 No Modeling of Noncommunicable Diseases Research Center, Institute of Health Sciences and Technologies, Avicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, Iran Fatemeh Nouri 100319475328460062 100319475328460062 No Department of Pharmaceutical Biotechnology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran